{
    "2021-07-15": [
        [
            {
                "time": "2021-07-30",
                "original_text": "招银证券：天坛生物(600161.SH)Q2业绩环比改善 预计全年业绩提速 维持“审慎推荐-A”评级",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "Q2业绩",
                        "环比改善",
                        "全年业绩提速",
                        "审慎推荐-A"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-05",
                "original_text": "太平洋维持天坛生物买入评级：业绩超预期，浆源获取能力强，浆量具备持续成长性",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "买入评级",
                        "业绩超预期",
                        "浆源获取能力",
                        "持续成长性"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-10",
                "original_text": "天坛生物（600161）2021H1业绩快报点评：业绩超预期，血制品业务增长潜力大！【东吴医药朱国广团队】",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "2021H1业绩",
                        "业绩超预期",
                        "血制品业务",
                        "增长潜力大"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-15",
                "original_text": "东吴证券维持天坛生物买入评级，2021上半年业绩快报点评：业绩超预期，血制品业务增长潜力大",
                "features": {
                    "keywords": [
                        "东吴证券",
                        "天坛生物",
                        "买入评级",
                        "2021上半年业绩",
                        "业绩超预期",
                        "血制品业务",
                        "增长潜力大"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}